Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.55 |
| ▸ | PPARG | P37231 | 4/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | FABP2 | P12104 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23544180 | 0.85 | ELANE (0.57) | ELANEPPARGPPARAFABP2SLC22A12 | |
| SCHEMBL23369295 | 0.83 | PPARG (0.43) | ELANEPPARGPPARAFABP2SLC22A12 | |
| SCHEMBL23899116 | 0.83 | ELANE (0.54) | ELANEPPARGPPARAFABP2SLC22A12 | |
| SCHEMBL19156186 | 0.83 | ELANE (0.54) | ELANEPPARGPPARAFABP2SLC22A12 | |
| SCHEMBL5281549 | 0.81 | ELANE (0.64) | ELANEPPARGPPARAFABP2SLC22A12 | |
| SCHEMBL5675865 | 0.80 | TAAR1 (0.46) | PPARGALDH1A1SMN1; SMN2 | |
| SCHEMBL19775908 | 0.80 | ELANE (0.51) | ELANEPPARGPPARAFABP2SLC22A12 | |
| SCHEMBL23369348 | 0.80 | PPARG (0.40) | ELANEPPARGPPARAFABP2SLC22A12 | |
| SCHEMBL9451181 | 0.79 | CYP19A1 (0.62) | MAPT | |
| SCHEMBL5156847 | 0.79 | CA1 (0.55) | STSL3MBTL1ALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2002-10-31 | — | — | US | disclosed |
| WO-2002066415-A2 | NON-STEROIDAL MODULATORS OF ESTROGEN RECEPTORS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | ESRRB, ESR2, ESRRG | ELANE 1218/4885PPARG 115/4885PPARA 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.